The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 201–300 of 1,002
Al-Warhi, T. I., Kerdawy, A. M. E., Aljaeed, N., Ismael, O. E., Ayyad, R. R. A., Eldehna, W. M., Abdel‐Aziz, H. A., & Al-Ansary, G. H. (2020) · Molecules · doi:10.3390/molecules25092031 · Cited by 96
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Kumarasamy, V., Vail, P., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2275 · Cited by 86
Self-citationDodge, M. J., MacNeil, K. M., Tessier, T. M., Weinberg, J. B., & Mymryk, J. S. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105034 · Cited by 96
Trotta, A. P., Gelles, J. D., Serasinghe, M. N., Loi, P., Arbiser, J. L., & Chipuk, J. E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786442 · Cited by 96
“However, given the level of redundancy across the CDK family (with the exception of CDK1), developing specific cell cycle inhibitors has thus far been problematic, whereas panCDK inhibitors are highly toxic (54).”
BackgroundA panoramic view of cell population dynamics in mammalian aging
Zhang, Z., Schaefer, C., Jiang, W., Lu, Z., Lee, J., Sziraki, A., Abdulraouf, A., Wick, B., Haeussler, M., Li, Z., et al. (2025) · Science · doi:10.1126/science.adn3949 · Cited by 95
Sammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 96
“Neutropenia is regularly experienced by patients treated with chemotherapy, yet neutropenia associated with CDK4/6 inhibitors differs both mechanistically (see below) in that, it is rapidly reversible [32].”
BackgroundSaqub, H., Proetsch-Gugerbauer, H., Bezrookove, V., Nosrati, M., Vaquero, E. M., de Semir, D., Ice, R. J., McAllister, S. D., Soroceanu, L., Kashani–Sabet, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75578-5 · Cited by 95
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Since then more than 60 phase I and phase II clinical trials in various cancers have been conducted using it (Asghar et al., 2015).”
BackgroundInfluentialSumi, N. J., Kuenzi, B. M., Knezevic, C. E., Remsing Rix, L. L., & Rix, U. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00368 · Cited by 84
CDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 76
RetractedThe emerging roles of CDK12 in tumorigenesis
Paculová, H., & Kohoutek, J. (2017) · Cell Division · doi:10.1186/s13008-017-0033-x · Cited by 95
“An increasing number of studies have pointed out the connection between individual transcriptional CDKs and cancerogenesis [5].”
InfluentialSonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E. H., Alba, E., Wist, E., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4523-y · Cited by 92
NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor
Bury, M., Calvé, B. L., Lessard, F., Maso, T. D., Saliba, J., Michiels, C., Ferbeyre, G., & Blank, V. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.087 · Cited by 92
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
Herbert, K. J., Ashton, T. M., Prevo, R., Pirovano, G., & Higgins, G. S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1131-7 · Cited by 92
Restriction point regulation at the crossroads between quiescence and cell proliferation
Pennycook, B. R., & Barr, A. R. (2020) · FEBS Letters · doi:10.1002/1873-3468.13867 · Cited by 92
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Chondrosarcoma-from Molecular Pathology to Novel Therapies
Zając, A. E., Kopeć, S., Szostakowski, B., Spalek, M. J., Fiedorowicz, M., Bylina, E., Filipowicz, P., Szumera‐Ciećkiewicz, A., Tysarowski, A., Czarnecka, A. M., et al. (2021) · Cancers · doi:10.3390/cancers13102390 · Cited by 91
“They have been validated as oncogenic drivers in severity malignancies, and increased expression of them are frequently found in cancers [188,189].”
BackgroundCombined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Song, X., Liu, X., Wang, H., Wang, J., Qiao, Y., Cigliano, A., Utpatel, K., Ribback, S., Pilo, M. G., Serra, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0284 · Cited by 92
“As palbociclib has been shown to inhibit tumor growth via inducing cell-cycle arrest (6, 13), we investigated the expression of cell cycle–related proteins in response to palbociclib treatment in the ICC cell lines (Fig.”
BackgroundCDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 91
Sabt, A., Eldehna, W. M., Al-Warhi, T. I., Alotaibi, O. J., Elaasser, M. M., Suliman, H. S., & Abdel‐Aziz, H. A. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1806259 · Cited by 89
“carboxylate (6) Ethyl 6-oxo dihydropyridazine-3-carboxylate derivative 5 (2 g, 8.”
MethodLücking, U., Kosemund, D., Böhnke, N., Lienau, P., Siemeister, G., Denner, K., Bohlmann, R., Briem, H., Terebesi, I., Bömer, U., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01000 · Cited by 89
Desnoyers, A., Nadler, M. B., Kumar, V., Saleh, R., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102086 · Cited by 89
Li, Y., Luo, X., Guo, Q., Nie, Y., Wang, T., Zhang, C., Huang, Z., Wang, X., Liu, Y., Chen, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00209 · Cited by 88
Hitting the brakes: targeting microtubule motors in cancer
Chandrasekaran, G., Tátrai, P., & Gergely, F. V. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.264 · Cited by 87
“Owing to its critical roles in organisms, complete inhibition of CDK1 is expected to be highly toxic; nonetheless there are pan CDK inhibitors in clinical trials that target CDK1 activity (summarised in Asghar et al (2015)).”
BackgroundExpression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Zhou, Y., Shen, J. K., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.004 · Cited by 87
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
Walter, D. M., Yates, T. J., Ruiz-Torres, M., Kim-Kiselak, C., Gudiel, A. A., Deshpande, C., Wang, W. Z., Cicchini, M., Stokes, K. L., Tobias, J. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1172-9 · Cited by 84
Causal Interactions from Proteomic Profiles: Molecular Data Meets Pathway Knowledge
Babur, Ö., Luna, A., Korkut, A., Durupınar, F., Siper, M. C., Doğrusöz, U., Jácome, A. S. V., Peckner, R., Christianson, K. E., Jaffe, J. D., et al. (2020) · Patterns · doi:10.1016/j.patter.2021.100257 · Cited by 89
Zhou, Y., Lih, T. M., Pan, J., Höti, N., Dong, M., Cao, L., Hu, Y., Cho, K.-C., Chen, S., Eguez, R. V., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01013-x · Cited by 86
“It is reported that the CDK4/6 relate to the regulation of the cell-cycle transition through retinoblastoma protein phosphorylation (pRb), while CDK2 contributes to the hyperphosphorylation of pRb and initiates DNA replication subsequently [54, 55] (Fig.”
BackgroundAn insight into the risk factors of brain tumors and their therapeutic interventions
Rasheed, S., Rehman, K., & Akash, M. S. H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112119 · Cited by 86
Roncato, R., Angelini, J., Pani, A., Cecchin, E., Bianchi, A. S., Siena, S., Mattia, E. D., Scaglione, F., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176350 · Cited by 85
“This promiscuity toward CDK isoforms often resulted in a jeopardizing inability to discriminate physiological and malignant proliferative processes, inducing severe cytotoxicity (myelosuppression and anemia) [36].”
BackgroundAyaz, P., Andres, D., Kwiatkowski, D., Kolbe, C., Lienau, P., Siemeister, G., Lücking, U., & Stegmann, C. M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00074 · Cited by 86
miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14
Ji, Q., Xu, X., Li, L., Goodman, S. B., Bi, W., Xu, M., Xu, Y., Fan, Z., Maloney, W. J., Ye, Q., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.499 · Cited by 84
“Moreover, abnormal functions of CDK proteins contribute to promote lung, breast, colorectal, ovarian and various other cancers, thereby suggesting that CDKs might be potential attractive targets for therapeutic intervention.(27,28,30,66) CDK14 expression directly increases with cancer progression.”
BackgroundCDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner
Prevo, R., Pirovano, G., Puliyadi, R., Herbert, K. J., Rodríguez‐Berriguete, G., O’Docherty, A., Greaves, W., McKenna, W. G., & Higgins, G. S. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1491236 · Cited by 84
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab, S., Yu, M., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01985 · Cited by 84
Phosphorylation regulates cullin-based ubiquitination in tumorigenesis
Chen, Y., Shao, X., Cao, J., Zhu, H., Yang, B., He, Q., & Ying, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.007 · Cited by 84
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 82
Girardi, D. M., Silva, A. C. B., Rêgo, J. F. M., Coudry, R. A., & Riechelmann, R. P. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.002 · Cited by 84
Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation
Azzarelli, R., Hurley, C., Sznurkowska, M. K., Rulands, S., Hardwick, L. J. A., Gamper, I., Ali, F. R., McCracken, L., Hindley, C. J., McDuff, F. K. E., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.004 · Cited by 84
“We noted that Roscovtitine and Palbociclib suppressed overall Ngn3 levels, consistent with off-target effects suppressing the transcriptional Cdks, Cdk7, and Cdk9 (Asghar et al., 2015).”
Ikeda, S., Tsigelny, I. F., Skjevik, Å. A., Kono, Y., Mendler, M. H., Kuo, A., Sicklick, J. K., Heestand, G. M., Banks, K. C., Talasaz, A. H., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0479 · Cited by 84
“The panel concluded that the CDKN2A R80* mutation is likely an inactivating mutation because it leads to truncation of the p16INK4a protein at amino acid 80 of 156 in the p16INK4a-encoding transcript, which lacks the third and fourth ankyrin repeat that binds to CDK4, and that CDKN2A p16INK4a loss of function should l…”
BackgroundClinical and molecular aspects of breast cancer: Targets and therapies
Godone, R. L. N., Leitão, G. M., Araújo, N., Castelletti, C. H. M., de Lima-Filho, J. L., & Martins, D. B. G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.066 · Cited by 84
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward
Khan, M. A., Azim, S., Zubair, H., Bhardwaj, A., Patel, G. K., Khushman, M. M., Singh, S., & Singh, A. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040779 · Cited by 83
“Therefore, loss of function of p16 results in the progression of the cell cycle through the G1/S checkpoint in an unrestricted manner, leading to the enhanced cell proliferation [74,75].”
BackgroundKanwal, N., Rasul, A., Hussain, G., Anwar, H., Shah, M. A., Sarfraz, I., Riaz, A., Batool, R., Shahbaz, M., Hussain, A., et al. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111570 · Cited by 82
CDK8 kinase—An emerging target in targeted cancer therapy
Rzymski, T., Mikuła, M., Wiklik, K., & Brzózka, K. D. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.05.011 · Cited by 82
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
Sathe, A., Koshy, N. R., Schmid, S. C., Thalgott, M. K., Schwarzenböck, S. M., Krause, B. J., Holm, P. S., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.08.082 · Cited by 84
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 83
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 81
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 82
“However, initial attempts to block CDK activity in patients were definitely unsuccessful, due to both the low therapeutic index and the high toxicity profiles that these pan-CDK inhibitors displayed, severely lowering the expectations for this type of targeted therapy (2).”
BackgroundRajput, S., Khera, N., Guo, Z., Hoog, J., Li, S., & Ma, C. X. (2016) · Oncotarget · doi:10.18632/oncotarget.10870 · Cited by 81
“CDKs play critical roles in regulating cell cycle transition and gene transcription, which are frequently altered in cancer [32].”
BackgroundHino, H., Iriyama, N., Kokuba, H., Kazama, H., Moriya, S., Takano, N., Hiramoto, M., Aizawa, S., & Miyazawa, K. (2020) · Cancer Science · doi:10.1111/cas.14419 · Cited by 80
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 82
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Xie, Z., Hou, S., Yang, X., Duan, Y., Han, J., Wang, Q., & Liao, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02190 · Cited by 80
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 80
“In multiple breast cancer clinical trials (Asghar et al, 2015; DeMichele et al, 2015; Finn et al, 2015, 2016; Cristofanilli et al, 2016; Hamilton & Infante, 2016; Sherr et al, 2016), PD0332991 combined with endocrine treatment substantially improved progression-free survival compared to endocrine…”
BackgroundInfluentialRecent Advances and Perspectives in Cancer Drug Design
Magalhães, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170823 · Cited by 80
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A. M., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10061334 · Cited by 80
“CDK4/6 Pathway Dysregulation in Melanoma Dysregulation of the p16ink4A-cyclin D-CDK4/6-RB pathway is common in many cancer types [16] and is recognized in up to 90% of melanomas, with alterations occurring in many nodes of this axis [6,17,18].”
BackgroundZhang, Z., Peng, H., Wang, X., Yin, X., Ma, P., Jing, Y., Cai, M., Liu, J., Zhang, M., Zhang, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0078 · Cited by 79
“We determined the requirement of other CDKs for ovarian tumorigenicity by Mol Cancer Ther; 16(9) September 2017 Molecular Cancer Therapeutics1742 knocking out each CDK gene using CRISPR-Cas9 technique.”
BackgroundInfluentialCDK 2 positively regulates aerobic glycolysis by suppressing SIRT 5 in gastric cancer
Tang, Z., Li, L., Tang, Y., Xie, D., Wu, K., Wei, W., & Xiao, Q. (2018) · Cancer Science · doi:10.1111/cas.13691 · Cited by 79
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma
Narita, T., Ishida, T., Ito, A., Masaki, A., Kinoshita, S., Suzuki, S., Takino, H., Yoshida, T., Ri, M., Kusumoto, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741983 · Cited by 78
PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution
Li, J., Dallmayer, M., Kirchner, T., Musa, J., & Grünewald, T. G. P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.002 · Cited by 77
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma
del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 80
“As opposed to Rad51 inhibitors, multiple CDK 1 and 2 inhibitors are already in clinical trials (62) and could potentially be repurposed for HR inhibition.”
BackgroundPatel, P. M., Tsiperson, V., Gottesman, S. R. S., Somma, J., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0602 · Cited by 77
“Proc Natl Acad Sci U S A 2010;107(1):58-63.”
BackgroundInfluentialLiu, X., Zhang, G., Yu, T., He, J., Liu, J., Chai, X., Zhao, G., Yin, D., & Zhang, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215781 · Cited by 75
Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer
Singh, R., & Purohit, R. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107367 · Cited by 75
Knudsen, E. S., Hutcheson, J., Vail, P. J., & Witkiewicz, A. K. (2017) · Oncotarget · doi:10.18632/oncotarget.18435 · Cited by 75
“The CDK4/6 inhibitors in advanced clinical testing fall into two broad categories based on toxicity-prolife and dosedelivery schedules [1-4].”
BackgroundInfluentialSelf-citationWu, D., Jia, H., Zhang, Z., & Li, S. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11585 · Cited by 74
Wei, D., Wang, H., Zeng, Q., Wang, W., Hao, B., Feng, X., Wang, P., Song, N., Kan, W., Huang, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01350 · Cited by 74
Targeting Phosphatases and Kinases: How to Checkmate Cancer
Turdo, A., D’Accardo, C., Glaviano, A., Porcelli, G., Colarossi, C., Colarossi, L., Mare, M., Faldetta, N., Modica, C., Pistone, G., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.690306 · Cited by 74
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
Li, Z., Ma, S., Zhang, L., Zhang, S., Ma, Z., Du, L., & Li, M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01648 · Cited by 74
Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 74
“Cancer cells may overcome the tumorsuppressive function of Rb by sustained activation of cyclin D/CDK4/6 or loss of Rb [11].”
BackgroundBreast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery
Craven, G. B., Affron, D. P., Allen, C. E., Matthies, S., Greener, J. G., Morgan, R. M. L., Tate, E. W., Armstrong, A., & Mann, D. J. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711825 · Cited by 73
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
Hsu, J. Y., Seligson, N. D., Hays, J. L., Miles, W. O., & Chen, J. L. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00211 · Cited by 73
Cherukupalli, S., Chandrasekaran, B., Kryštof, V., Aleti, R. R., Sayyad, N., Merugu, S. R., Kushwaha, N. D., & Karpoormath, R. V. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.030 · Cited by 73
Shi, Z., Tian, L., Qiang, T., Li, J., Xing, Y. Q., Ren, X., Liu, C., & Liang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02064 · Cited by 72
CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 72
Zhang, H., Zhu, C., Zhao, Y. C., Li, M., Wu, L., Yang, X., Wan, X., Wang, A., Zhang, M. Q., Sang, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6087 · Cited by 72
“Cyclin-dependent kinases (CDKs), which are key regulators of the cell cycle, have been investigated as potential therapeutic targets for cancer [34].”
BackgroundCell Cycle Regulation and Melanoma
Xu, W., & McArthur, G. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0524-y · Cited by 73
Cooperative p16 and p21 action protects female astrocytes from transformation
Kfoury, N., Sun, T., Yu, K., Rockwell, N., Tinkum, K. L., Qi, Z., Warrington, N. M., McDonald, P. R., Roy, A., Weir, S. J., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0513-5 · Cited by 72
Singh, U., Chashoo, G., Khan, S. U., Mahajan, P., Nargotra, A., Mahajan, G., Singh, A., Sharma, A., Mintoo, M. J., Guru, S. K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00663 · Cited by 72
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
Husna, S. M. N., Tan, H. T., Mohamud, R., Dyhl-Polk, A., & Wong, K. K. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918808509 · Cited by 71
“p85α, p85β, p55γ, p101 or p84)] in the PI3K/AKT kinase signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and activation of the PI3K signaling pathway.”
BackgroundBelal, A., Gawad, N. M. A., Mehany, A. B. M., Abourehab, M. A. S., Elkady, H., Al-Karmalawy, A. A., & Ismael, A. S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2096019 · Cited by 71
Molecular mechanisms and therapeutic targets in pediatric brain tumors
Liu, K.-W., Pajtler, K. W., Worst, B. C., Pfister, S. M., & Wechsler‐Reya, R. J. (2017) · Science Signaling · doi:10.1126/scisignal.aaf7593 · Cited by 71
CDK4/6 inhibitors: a brief overview and prospective research directions
Adon, T., Shanmugarajan, D., & Kumar, H. Y. (2021) · RSC Advances · doi:10.1039/d1ra03820f · Cited by 71
Novel Molecular Markers for Breast Cancer
Inoue, K., & Fry, E. A. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s38394 · Cited by 70
Toward precision medicine of breast cancer
Carels, N., Spinassé, L. B., Tilli, T. M., & Tuszyński, J. A. (2016) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-016-0035-4 · Cited by 70
“CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in substantial clinical activity [101].”
BackgroundGermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases
Helgadóttir, H., Höiom, V., Tuominen, R., Nielsen, K., Jönsson, G. B., Olsson, H. L., & Hansson, J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw135 · Cited by 70
Wang, H., Yuan, S., Zheng, Q., Zhang, S., Zhang, Q., Ji, S., Wang, W. J., Cao, Y., Guo, Y., Yang, X., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.025 · Cited by 69
Hsieh, F., Chen, Y., Hung, M., Chu, P., Tsai, M., Chen, L., Hsiao, Y., Shih, C., Chang, M.-J., Chao, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12072 · Cited by 70
“It has been generally believed that the CDK4/6-RB/E2F axis mediates the molecular activity of palbociclib (Asghar et al., 2015); however, recently, the antiproliferative effect of palbociclib in HCC cells has been examined, and interestingly, palbociclib showed activity irrespective of RB status in HCC cells and tumor…”
BackgroundCDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors
Xi, M., Chen, T., Wu, C., Gao, X., Wu, Y., Luo, X., Du, K., Yu, L., Cai, T., Shen, R., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.076 · Cited by 69
Kuang, Y., Guo, W., Jing, L., Xu, D., Liao, Y., Zhao, H., Du, X., Wang, H., Xu, M., Song, H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1528-y · Cited by 69
To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response
Liu, Q., Gao, J., Zhao, C., Guo, Y., Wang, S., Shen, F., Xing, X., & Luo, Y. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102702 · Cited by 68
El‐Naggar, A. M., El-Hashash, M. A. A., & Elkaeed, E. B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104615 · Cited by 68
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 68
“Proliferation stimuli, including those through KRAS, converge on the complex CDK4/6 cyclin-D, a critical regulator of the transition between phase G1 and S [84].”
BackgroundCombined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Olmez, I., Zhang, Y., Manigat, L. C., Benamar, M., Brenneman, B. R., Nakano, I., Godlewski, J. A., Bronisz, A., Lee, J., Abbas, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3124 · Cited by 69
“CDK4/6 inhibitors are the sole group of cell-cycle inhibitors now in the clinic, with FDA approval for hormone receptor-positive breast cancers and tumors with loss of p16 or increased cyclin D1 (7, 8).”
BackgroundThe multifaceted allosteric regulation of Aurora kinase A
Levinson, N. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170771 · Cited by 65
Integrative proteogenomic characterization of early esophageal cancer
Li, L., Jiang, D., Zhang, Q., Liu, H., Xu, F., Guo, C., Qin, Z., Wang, H., Feng, J., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37440-w · Cited by 67
Li, X., Zhou, Y., Liu, Y., Zhang, X., Chen, T., Chen, K., Ba, Q., Li, J., Liu, H., & Wang, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.026 · Cited by 67
“Tumor masses were calculated by caliper measurements using the formula “1/2a × b(Asghar et al., 2015)”, where “a” is the long diameter and “b” is the short diameter (in mm).”
BackgroundMethodBiological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogs
Pinheiro, S., Pinheiro, E. M. C., Muri, E. M. F., Pessôa, J. C., Cadorini, M. A., & Greco, S. J. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02609-1 · Cited by 67
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Zabihi, M., Lotfi, R., Yousefi, A., & Bashash, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04135-6 · Cited by 67
Ye, L., Guo, L., He, Z., Wang, X., Lin, C., Zhang, X., Wu, S., Bao, Y., Yang, Q., Song, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8121 · Cited by 67
Shukla, R., & Singh, T. R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1571947 · Cited by 67
“Various studies also suggest the novel CDK5 inhibitors in recent years (Asghar et al., 2015; Demange, Abdellah et al., 2013; Demange, Lozach et al., 2013; Helal et al., 2004; Jain et al., 2011, p. 25; Kaller et al., 2009; Kunick et al., 2004; Mapelli & Musacchio, 2003, p. 5; Mapelli et al., 2005;…”
Background
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.